In vitro induction of regulatory T cells by anti-CD3 antibody in humans

Journal of Autoimmunity

Volumn 30, Issue 1-2, 2008, Pages 21-28

  Abraham, Michal ^a   Karni, Arnon ^a   Dembinsky, Adi ^a   Miller, Ariel ^b   Gandhi, Roopali ^a   Anderson, David ^a   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

Anti CD3; Autoimmunity; Regulatory T cells

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY CD28; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANTIBODIES; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD3; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 38049007455     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.11.007     Document Type: Article

References (38)

1. Machado P.G., Tedesco H.S., Silva R.G., Pacheco-Silva A., and Medina J.O. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation. Transplant Proc 34 (2002) 104
2. Go M.R., and Bumgardner G.L. OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient. Transplantation 73 (2002) 1957
3. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., and Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9 (2003) 1202
4. Tran G.T., Carter N., He X.Y., Spicer T.S., Plain K.M., Nicolls M., et al. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4. Int Immunol 13 (2001) 1109
5. Kohm A.P., Williams J.S., Bickford A.L., McMahon J.S., Chatenoud L., Bach J.F., et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4 + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174 (2005) 4525
6. Farges O., Ericzon B.G., Bresson-Hadni S., Lynch S.V., Hockerstedt K., Houssin D., et al. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Transplantation 58 (1994) 891
7. Gilbert E.M., Dewitt C.W., Eiswirth C.C., Renlund D.G., Menlove R.L., Freedman L.A., et al. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med 82 (1987) 202
8. Masteller E.L., and Bluestone J.A. Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol 14 (2002) 652
9. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 (2002) 1692
10. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005) 2598
11. Bresson D., and von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?. Autoimmun Rev 6 (2007) 315
12. Utset T.O., Auger J.A., Peace D., Zivin R.A., Xu D., Jolliffe L., et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29 (2002) 1907
13. Mottram P.L., Murray-Segal L.J., Han W., Maguire J., and Stein-Oakley A.N. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. Transpl Immunol 10 (2002) 63
14. Wesselborg S., Janssen O., and Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150 (1993) 4338
15. Janssen O., Wesselborg S., and Kabelitz D. Immunosuppression by OKT3-induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 53 (1992) 233
16. Wong J.T., and Colvin R.B. Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis. Clin Immunol Immunopathol 58 (1991) 236
17. Jung G., Martin D.E., and Muller-Eberhard H.J. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. J Immunol 139 (1987) 639
18. Zhang L., Yi H., Xia X.P., and Zhao Y. Transforming growth factor-beta: an important role in CD4+ CD25+ regulatory T cells and immune tolerance. Autoimmunity 39 (2006) 269
19. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A.S., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med 12 (2006) 627
20. Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., et al. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10 (1998) 1969
21. Chang X., Zheng P., and Liu Y. FoxP3: a genetic link between immunodeficiency and autoimmune diseases. Autoimmun Rev 5 (2006) 399
22. Chatenoud L. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr Opin Immunol 17 (2005) 632
23. Holzer U., Rieck M., and Buckner J.H. Lineage and signal strength determine the inhibitory effect of transforming growth factor beta1 (TGF-beta1) on human antigen-specific Th1 and Th2 memory cells. J Autoimmun 26 (2006) 241
24. Vendetti S., Chai J.G., Dyson J., Simpson E., Lombardi G., and Lechler R. Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol 165 (2000) 1175
25. Frasca L., Scotta C., Lombardi G., and Piccolella E. Human anergic CD4+ T cells can act as suppressor cells by affecting autologous dendritic cell conditioning and survival. J Immunol 168 (2002) 1060
26. Wildin R.S., and Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun 25 Suppl (2005) 56
27. Bacchetta R., Gregori S., and Roncarolo M.G. CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun Rev 4 (2005) 491
28. Andreoli L., Pregnolato F., Burlingame R., Allegri F., Rizzini S., Fanelli V., et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity. J Autoimmun 30 (2008) 84-89
29. Andreoli L., Pregnolato F., Burlingame R., Allegri F., Rizzini S., Fanelli V., et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity. J Autoimmun 30 (2008) 51-57
30. Binard A., Le Pottier L., Saraux A., Devauchelle-Pensec V., Pers J.-O., and Youinou P. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?. J Autoimmun 30 (2008) 63-67
31. Jacobson E., Huber A., and Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 30 (2008) 58-63
32. Kallenberg C. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 30 (2008) 29-36
33. Mackay I., Leskovek N., and Rose N. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
34. Nakanishi Y., Tsuneyama K., Fujimoto M., Thucydides L., Nomoto K., An J.-L., et al. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J Autoimmun 30 (2008) 42-50
35. Poletaev A., Stepanyuk V., and Gershwin M. Integrating immunity: the immunculus and self reactivity. J Autoimmun 2008 30 (2007) 68-73
36. Praprotnik S., Snezna S.-S., Tomsic M., and Shoenfeld Y. The curiously suspicious: infectious disease may ameliorate an ongoing autoimmune destruction in systemic lupus erythematosus patients. J Autoimmun 30 (2008) 37-41
37. Sanchez-Pernaute O., Ospelt C., Neidhart M., and Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 30 (2008) 12-20
38. Shoenfeld Y., and Gershwin M. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 30 (2008) 1-4